Kitahama Keiichiro, Iijima Shohei, Sumiishi Ayumi, Hayashi Akimasa, Nagahama Kiyotaka, Saito Kuniaki, Sasaki Nobuyoshi, Kobayashi Keiichi, Shimizu Saki, Nagane Motoo, Shibahara Junji
Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
Department of Neurosurgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
Brain Tumor Pathol. 2021 Jan;38(1):23-29. doi: 10.1007/s10014-020-00382-y. Epub 2020 Sep 28.
Trimethylation of histone H3 at lysine 27 (H3K27me3) acts as a transcriptional repressor of target genes. Recent immunohistochemical studies have reported a loss of H3K27me3 modification in diffuse (especially 1p/19q-codeleted) gliomas. However, we did not observe H3K27me3 loss in diffuse gliomas using routine immunostaining conditions for the detection of H3K27me3 loss in malignant peripheral nerve sheath tumors (MPNSTs). Therefore, we conducted immunohistochemical analysis of surgically resected specimens to understand the differences in the H3K27me3 status in MPNSTs and diffuse gliomas and evaluate the diagnostic utility of H3K27me3 immunohistochemistry. Staining with a standard 1:200 dilution of the C36B11 antibody showed a complete loss of H3K27me3 in 5 out of 11 MPNSTs, whereas most diffuse gliomas (149/151, 98.7%) showed diffuse immunoreactivity. At a 1:2000 antibody dilution, 12.6% (19/151) of the diffuse gliomas showed H3K27me3 loss, which was significantly associated with 1p/19q codeletion (P < 0.001). H3K27me3 loss predicted 1p/19q codeletion in IDH-mutant gliomas with lower sensitivity (56.2%) and higher specificity (100%) than ATRX retention or p53 negative result. In conclusion, reduction in H3K27me3 levels was associated with 1p/19q codeletion in diffuse gliomas; however, the extent of reduction differed from that in MPNSTs, and the results depended on the immunostaining conditions.
组蛋白H3赖氨酸27位点的三甲基化(H3K27me3)作为靶基因的转录抑制因子。最近的免疫组织化学研究报道,弥漫性(尤其是1p/19q共缺失型)胶质瘤中存在H3K27me3修饰缺失。然而,我们在检测恶性外周神经鞘瘤(MPNSTs)中H3K27me3缺失的常规免疫染色条件下,未在弥漫性胶质瘤中观察到H3K27me3缺失。因此,我们对手术切除标本进行免疫组织化学分析,以了解MPNSTs和弥漫性胶质瘤中H3K27me3状态的差异,并评估H3K27me3免疫组织化学的诊断效用。用标准的1:200稀释的C36B11抗体染色显示,11例MPNSTs中有5例H3K27me3完全缺失,而大多数弥漫性胶质瘤(149/151,98.7%)显示弥漫性免疫反应。在抗体稀释度为1:2000时,12.6%(19/151)的弥漫性胶质瘤显示H3K27me3缺失,这与1p/19q共缺失显著相关(P < 0.001)。H3K27me3缺失在IDH突变型胶质瘤中预测1p/19q共缺失的敏感性较低(56.2%),特异性较高(100%),低于ATRX保留或p53阴性结果。总之,弥漫性胶质瘤中H3K27me3水平降低与1p/19q共缺失有关;然而,降低程度与MPNSTs不同,结果取决于免疫染色条件。